Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

NHS failing to promote clinical trials to patients

NIHR mystery shoppers report says 91 per cent of sites have no information in reception area

- PMLiVE

Amgen signs $180m nanotechnology cancer deal

Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug

- PMLiVE

India’s Supreme Court wants tighter clinical trial regulation

Justice Lodha says illegal studies of investigational medicines causing “havoc to human life”

- PMLiVE

EMA to focus on efficiency, transparency and new legislation in 2013

Regulator also plans significant staff reorganisation

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Amgen offers $762m to end Aranesp lawsuits

Pleads guilty to illegal marketing of anaemia drug

- PMLiVE

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

- PMLiVE

Amgen continues spending spree, acquires deCode Genetics

Will pay $415m for Icelandic genetic information firm

- PMLiVE

EMA: move to greater clinical trial transparency ‘irreversible’

New Europe data rules could be ready by 2014

- PMLiVE

MP: Daiichi Sankyo’s expansion is endorsement of UK life sciences

Pharma company enlarges its UK early-stage development base

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links